Использование нимодипина (Нимотопа) при когнитивных нарушениях


И.В. Дамулин

Кафедра нервных болезней ММА им. И.М. Сеченова, Москва
В статье рассматриваются механизмы действия и клинический эффект блокатора кальциевых каналов нимодипина. Подчеркивается, что в настоящее время этот препарат применяют при субарахноидальном кровоизлиянии, ишемическом инсульте и деменциях различного (сосудистого и первично-дегенеративного) генеза. Этот препарат не только действует симптоматически, улучшая когнитивные и поведенческие функции у пациентов с деменцией, но и способен влиять на механизмы развития когнитивных расстройств. Побочные эффекты на фоне терапии встречаются редко, что представляется особенно важным для пациентов пожилого и старческого возраста.
Ключевые слова: нимодипин, лечение, деменция

Литература


1. Андреев Н.А., Моисеев В.С. Антагонисты кальция в клинической медицине. М., 1995. 161 с.


2. Козловский В.Л. Влияние блокаторов кальциевых каналов на эффективность галоперидола и фенамина у мышей и крыс // Экспериментальная и клиническая фармакология. 1996. Т. 59. С. 12–15.


3. Стаховская Л.В., Чекнева Н.С. Нимотоп С в лечении цереброваскулярной патологии. Методические рекомендации / Под ред. Л.Г. Ерохиной. М., 1995. 20 с.


4. Яхно Н.Н. Когнитивные расстройства в неврологической клинике // Неврологический журнал. 2006. Т. 11. Прилож. 1. С. 4–12.


5. Avery RB, Johnston D. Multiple channel types contribute to the low-voltage-activated calcium current in hippocampal CA3 pyramidal neurons. J Neurosci 1996;16:5567–82.


6. Ban TA, Morey L, Aguglia E, et al. Nimodipine in the treatment of old age dementias. Prog Neuro-Psychopharmacol Biol Psychiatr 1990;14:525–51.


7. Besson JAO, Palin AN, Ebmeyer KP, et al. Calcium antagonists and multi-infarct dementia: a trial involving sequential NMR and psychometric assessment. Intern J Geriatr Psychiatry 1988;3:99–105.


8. Campbell LW, Hao SY, Thibault O, et al. Aging changes in voltage-gated calcium currents in hippocampal CA1 neurons. J Neurosci 1996;16:6286–95.


9. De Riu PL, Demontis MP, Anania V, et al. Brain electrobiogenesis protection induced by nimodipine and MK-801 during acute hypoxia in hypertensive rats. Pharmacol Res 1995;31:169–73.


10. Eicher H, Hilgert D, Zeeh J, et al. Pharmacokinetics of nimodipine in multimorbid elderly patients with chronic brain failure. Arch Gerontol Geriatr 1992;14:309–19.


11. Ercan M, Inci S, Kilinc K, et al. Nimodipine attenuates lipid peroxidation during the acute phase of head trauma in rats. Neurosurg Rev 2001;24:127–30.


12. Erkinjuntti T. Subcortical vascular dementia – diagnostic problems. In: 7th IPA Congress. Sydney, Australia, 1995:45.


13. Ferszt R, Kanowski S. Nimodipine in the treatment of dementia. Drugs Today 1998;34:767–76.


14. Frisoni GB, Galluzzi S, Bresciani L, et al. Mild cognitive impairment with subcortical vascular features. Clinical characteristics and outcome. J Neurol 2002;249:1423–32.


15. Grobe-Einsler R. Clinical aspects of nimodipine. Neurobiol Aging 1993;13:S39–45.


16. Hauerberg J, Rasmussen G, Juhler M, et al. The effect of nimodipine on autoregulation of cerebral blood flow after subarachnoid haemorrhage in rat. Acta Neurochir (Wien) 1995;132:98–103.


17. Herz RC, De Wildt DJ, Versteeg DH. The effects of gamma 2-melanocyte-stimulating hormone and nimodipine on cortical blood flow and infarction volume in two rat models of middle cerebral artery occlusion. Eur J Pharmacol 1996;306:113–21.


18. Kabuto H, Yokoi I, Mori A. Neurochemical changes related to ageing in the senescenceaccelerated mouse brain and the effect of chronic administration of nimodipine. Mech Ageing Dev 1995;80:1–9.


19. Kanowski S, Fischhov P, Hiersemenzel R, et al. Therapeutic efficacy of nootropic drugs – a discussion of clinical phase III studies with nimodipine as a model. In: Diagnosis and treatment of senile dementia. M. Bergener, B. Reisberg (Eds.). Berlin etc.: Springer-Verlag 1989:339–49.


20. Kazda S, Gartoff B, Krause HP, et al. Cerebrovascular effects of calcium antagonistic dihydropyidine deriviative nimodipine in animal experiments. Drugs Res 1982;32:331–38.


21. Korenkov AI, Pahnke J, Frei K, et al. Treatment with nimodipine or mannitol reduces programmed cell death and infarct size following focal cerebral ischemia. Neurosurg Rev 2000;23:145–50.


22. Knopman DS. Treatment of mild cognitive impairment and prospects for prevention of Alzheimer's disease. In: Mild Cognitive Impairment: Aging to Alzheimer's Disease. Ed. by R.C.Petersen. Oxford: Oxford University Press 2003:243–58.


23. Landfield PW. Calcium homeostasis in brain ageing and Alzheimer’s disease. In: Diagnosis and Treatment of Senile Dementia. Ed by. M.Bergener, B.Reisberg. Berlin: Springer Verlag 1989:276–87.


24. Levere TE, Walker A. Old age and cognition enhancement of recent memory in aged rats by the calcium channel blocker nimodipine. Neurobiol Aging 1991;13:63–66.


25. Lopez-Arrieta J. Nimodipine. /In: Evidencebased Dementia Practice. Ed. by N.Qizilbash et al. Oxford: Blackwell Science 2002:537–40.


26. Luiten PG, Douma BR, Van der Zee EA, et al. Neuroprotection against NMDA induced cell death in rat nucleus basalis by Ca2+ antagonist nimodipine, influence of aging and developmental drug treatment. Neurodegeneration 1995;4:307–14.


27. Lustig HS, Ahern KB, Greenberg DA. Omega-agatoxin IVA and excitotoxicity in cortical neuronal cultures. Neurosci Lett 1996;213:142–44.


28. Nomura M. Effect of nimodipine on brightness discrimination learning test in Wistar Kyoto and spontaneously hypertensive rats. Drugs Res 1988;38:1282–86.


29. Noskovic P, Faberova V, Fabianova M. Effect of a combination of pentoxifylline and nimodipine on lipid peroxidation in postischemic rat brain. Mol Chem Neuropathol 1995;25:97–102.


30. Pantoni L, Rossi R, Inzitari D, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J Neurol Sci 2000;175:124–34.


31. Pantoni L, del Ser T, Soglian AG, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebocontrolled trial. Stroke 2005;36:619–24.


32. Sandin M, Jasmin S, Levere T. Aging and cognition. Facilitation of recent memory in aged nonhuman primates by nimodipine. Neurobiol Aging 1990;11:573–75.


33. Scriabine A. Pharmacology overview: Nimodipine in CNS indications. In: Nimodipine: Pharmacological and clinical results in cerebral ischemia. A.Scriabine et al (Eds.). Berlin etc.: Springer-Verlag 1991:1–7.


34. Sobrado M, Lopez MG, Carceller F, et al. Combined nimodipine and citicoline reduce infarct size, attenuate apoptosis and increase bcl-2 expression after focal cerebral ischemia. Neuroscience 2003;118:107–13.


35. Stuiver BT, Douma BR, Bakker R, et al. In vivo protection against NMDA-induced neurodegeneration by MK-801 and nimodipine: combined therapy and temporal course of protection. Neurodegeneration 1996;5:153–59.


36. Sze KH, Sim TC, Wong E, et al. Effect of nimodipine on memory after cerebral infarction. Acta Neurol Scand 1998;97: 386–92.


37. Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatr 1990;27:1133–42.


38. Tomassoni D, Lanari A, Silvestrelli G, et al. Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies. Clin Exp Hypert 2008;30:744–66.


39. Viveros MP, Martin S, Ormazabal M, et al. Effects of nimodipine and nifedipine upon behavior and regional brain monoamines in the rat. Psychopharmacology (Berl.) 1996;127:123–32.


40. Yanpallewar SU, Hota D, Rai S, et al. Nimodipine attenuates biochemical, behavioral and histopathological alterations induced by acute transient and long-term bilateral common carotid occlusion in rats. Pharmacol Res 2004;49:143–50.


Похожие статьи


Бионика Медиа